Please login to the form below

Not currently logged in
Email:
Password:

cervical cancer

This page shows the latest cervical cancer news and features for those working in and with pharma, biotech and healthcare.

AZ’s comeback drug cediranib stumbles in phase 3 trial

AZ’s comeback drug cediranib stumbles in phase 3 trial

and cervical cancer indications, particularly the ICON6 study sponsored by Cancer Research UK. ... That results led to speculation that the combination could become a chemo-free option for relapsed ovarian cancer patients.

Latest news

  • Merck CFO: we’re not only about Keytruda Merck CFO: we’re not only about Keytruda

    He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer ... Merck is also conducting a trial of Keytruda

  • Cancer Research UK among partners in new international research alliance Cancer Research UK among partners in new international research alliance

    CRUK acknowledged that although existing screening programmes for some cancers, including bowel, breast and cervical cancer, have seen great improvement, there are still many cancer types which have no screening methods, ... Benefits for patients will

  • GSK eyes follow-up HPV vaccine GSK eyes follow-up HPV vaccine

    Innovax has already developed a cervical cancer vaccine, Cecolin, which is HPV 16 &18 bivalent – these two HPV types are known to cause at least 70% of cervical cancers. ... Under the agreement, Innovax said it and GSK “will continuously support the

  • Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

    Cases of the skin cancer are increasing in certain European countries, there is little on the market for those suffering with advanced stages of the disease. ... cell carcinoma and cervical cancer.

  • Iovance up on good ASCO abstract data for cervical cancer therapy Iovance up on good ASCO abstract data for cervical cancer therapy

    The headline news is data from the cervical cancer trial of LN-145, which revealed an overall response rate (ORR) of 44% in recurrent cervical cancer, with 89% of patients showing ... That compares very well with results seen with Merck &Co’s PD-1

More from news
Approximately 9 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The approach is however also set to be tested as an in vivo therapy for cervical cancer caused by human papillomavirus (HPV) by researchers in China,

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Immunisation politicised Immunisation politicised

    human papilloma virus (HPV), including strains that lead to cervical cancer. ... Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test

  • Pharma deals in August 2015 Pharma deals in August 2015

    Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine Pharmaceuticals. Combination clinical trials. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.

  • Country report: The healthcare market in Brazil Country report: The healthcare market in Brazil

    In September 2011, the government announced the funding of programmes that prevent, diagnose and treat cervical and breast cancer. ... AIDS, cancer, diabetes and less common conditions such as Chagas disease and endometriosis, covering around 400, 000

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics